Determinants of stigma among patients with hepatitis C virus infection
© 2020 John Wiley & Sons Ltd..
Stigma around hepatitis C virus (HCV) infection is an important and understudied barrier to HCV treatment and elimination. The determinants of HCV-related stigma, including the impacts of stage of HCV treatment (ie spontaneously cleared; diagnosed, untreated; previously treated, not cured; currently being treated; and treated, cured) and coinfection with human immunodeficiency virus (HIV), remain unknown. To address these gaps, we conducted a cross-sectional study among patients with a history of HCV infection (n = 270) at outpatient clinics in Philadelphia from July 2018 to May 2019. We evaluated stigma using the validated HCV Stigma Scale, adapted from the Berger HIV Stigma Scale. Associations among HCV-related stigma and hypothesized demographic, behavioural, and clinical risk factors were evaluated by multivariable linear regression. Most participants (95.5%) experienced HCV-related stigma. Mean stigma scores did not differ significantly between HCV-monoinfected and HIV/HCV-coinfected participants (P = .574). However, we observed significant interactions between HIV status and multiple determinants; therefore, we stratified analyses by HIV status. Among HIV/HCV-coinfected participants, previous HCV treatment without cure, female gender, Hispanic/Latinx ethnicity and some college education were significantly associated with higher HCV-stigma scores. An annual income of $10 000-$40 000 was associated with significantly lower stigma scores. No significant associations were observed among HCV-monoinfected participants. We found that most participants experienced stigma associated with HCV diagnosis. While stigma scores were similar between HCV-monoinfected and HIV/HCV-coinfected participants, the determinants associated with HCV stigma differed by HIV status. Understanding how experiences of stigma differ between HCV-monoinfected and HIV/HCV-coinfected patients may aid in the development of targeted interventions to address the HCV epidemic.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:27 |
|---|---|
| Enthalten in: |
Journal of viral hepatitis - 27(2020), 11 vom: 06. Nov., Seite 1179-1189 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Saine, M Elle [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Determinants |
|---|
| Anmerkungen: |
Date Completed 25.08.2021 Date Revised 22.08.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/jvh.13343 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM310801923 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM310801923 | ||
| 003 | DE-627 | ||
| 005 | 20231225140857.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/jvh.13343 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1035.xml |
| 035 | |a (DE-627)NLM310801923 | ||
| 035 | |a (NLM)32500618 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Saine, M Elle |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Determinants of stigma among patients with hepatitis C virus infection |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.08.2021 | ||
| 500 | |a Date Revised 22.08.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2020 John Wiley & Sons Ltd. | ||
| 520 | |a Stigma around hepatitis C virus (HCV) infection is an important and understudied barrier to HCV treatment and elimination. The determinants of HCV-related stigma, including the impacts of stage of HCV treatment (ie spontaneously cleared; diagnosed, untreated; previously treated, not cured; currently being treated; and treated, cured) and coinfection with human immunodeficiency virus (HIV), remain unknown. To address these gaps, we conducted a cross-sectional study among patients with a history of HCV infection (n = 270) at outpatient clinics in Philadelphia from July 2018 to May 2019. We evaluated stigma using the validated HCV Stigma Scale, adapted from the Berger HIV Stigma Scale. Associations among HCV-related stigma and hypothesized demographic, behavioural, and clinical risk factors were evaluated by multivariable linear regression. Most participants (95.5%) experienced HCV-related stigma. Mean stigma scores did not differ significantly between HCV-monoinfected and HIV/HCV-coinfected participants (P = .574). However, we observed significant interactions between HIV status and multiple determinants; therefore, we stratified analyses by HIV status. Among HIV/HCV-coinfected participants, previous HCV treatment without cure, female gender, Hispanic/Latinx ethnicity and some college education were significantly associated with higher HCV-stigma scores. An annual income of $10 000-$40 000 was associated with significantly lower stigma scores. No significant associations were observed among HCV-monoinfected participants. We found that most participants experienced stigma associated with HCV diagnosis. While stigma scores were similar between HCV-monoinfected and HIV/HCV-coinfected participants, the determinants associated with HCV stigma differed by HIV status. Understanding how experiences of stigma differ between HCV-monoinfected and HIV/HCV-coinfected patients may aid in the development of targeted interventions to address the HCV epidemic | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a HIV infection | |
| 650 | 4 | |a determinants | |
| 650 | 4 | |a hepatitis C | |
| 650 | 4 | |a stigma | |
| 650 | 4 | |a syndemic | |
| 700 | 1 | |a Szymczak, Julia E |e verfasserin |4 aut | |
| 700 | 1 | |a Moore, Tyler M |e verfasserin |4 aut | |
| 700 | 1 | |a Bamford, Laura P |e verfasserin |4 aut | |
| 700 | 1 | |a Barg, Frances K |e verfasserin |4 aut | |
| 700 | 1 | |a Schnittker, Jason |e verfasserin |4 aut | |
| 700 | 1 | |a Holmes, John H |e verfasserin |4 aut | |
| 700 | 1 | |a Mitra, Nandita |e verfasserin |4 aut | |
| 700 | 1 | |a Lo Re, Vincent |c 3rd |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of viral hepatitis |d 1997 |g 27(2020), 11 vom: 06. Nov., Seite 1179-1189 |w (DE-627)NLM074659642 |x 1365-2893 |7 nnns |
| 773 | 1 | 8 | |g volume:27 |g year:2020 |g number:11 |g day:06 |g month:11 |g pages:1179-1189 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/jvh.13343 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 27 |j 2020 |e 11 |b 06 |c 11 |h 1179-1189 | ||